M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Stopped Due to the fact that the sponsor decided not to move forward with the development of M7824
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8
Interventions
- DRUG: Bintrafusp Alfa
- DRUG: Eribulin Mesylate
Sponsor
M.D. Anderson Cancer Center
Collaborators